Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul Ashton is active.

Publication


Featured researches published by Paul Ashton.


International Journal of Pharmaceutics | 1992

Surfactant effects in percutaneous absorption I. Effects on the transdermal flux of methyl nicotinate

Paul Ashton; Kenneth A. Walters; Keith Roger Brain; Jonathan Hadgraft

Abstract We have investigated the effects of a series of surfactants on the permeability of human skin in vitro using methyl nicotinate as a model drug. The surfactants used were cetyl trimethyl ammonium bromide, sodium lauryl sulphate, decyl methyl sulphoxide and Brij 36T. These surfactants have a linear alkyl chain of 10–12 units linked to different hydrophilic groups. We found that while the ionic surfactant exerted a greater effect on the flux of methyl nicotinate, the nonionic surfactants had a smaller but more immediate effect on the flux. This is consistent with the hypothesis that for compounds to disturb the permeability barrier of the stratum corneum they must first penetrate it themselves. Ionic compounds can be expected to penetrate this lipophilic barrier more slowly than nonionic compounds of a similar structure and therefore will take longer to elicit their effects.


Retina-the Journal of Retinal and Vitreous Diseases | 1993

Clearance and distribution of ciprofloxacin after intravitreal injection.

Pearson Pa; Hainsworth Dp; Paul Ashton

This study was designed to determine the drug concentration and clearance after intravitreal injection of ciprofloxacin. Ciprofloxacin (100 micrograms/0.1 cc) was injected into the vitreous of normal eyes and into eyes that had undergone lensectomy and vitrectomy. Drug concentration was determined using high-pressure liquid chromatography analysis 0.5, 2, 4, and 12 hours after injection. In normal eyes, the elimination half life was 2.2 hours with a distribution volume of 1.2 ml. In aphakic vitrectomized eyes, the half life was 1 hour and the distribution volume was 1.4 ml. The majority of the drug appears to leave via a transretinal route, but clearance was not inhibited by probenecid. Because of the relatively short half life, intravitreal administration of ciprofloxacin for the treatment of endophthalmitis would provide only short-term therapy and would need to be supplemented by other forms of treatment.


International Journal of Pharmaceutics | 1992

Surfactant effects in percutaneous absorption II. Effects on protein and lipid structure of the stratum corneum

Paul Ashton; Kenneth A. Walters; Keith Roger Brain; Jonathan Hadgraft

Abstract The effects of several known penetration enhancers on the lipid structure of human stratum corneum have been investigated by differential scanning calorimetry. Effects on the birefringence were also examined. A correlation was found to exist between the ability of a compound to increase the birefringence of the stratum corneum and its reported tendency to induce local irritation when applied to the skin.


Journal of The Chemical Society, Chemical Communications | 1995

Reaction of N-benzoyl amino acids with oxalyl chloride: a facile route to 4-substituted 2-phenyloxazole-5-carboxylates

Tadeusz Cynkowski; Grazyna Cynkowska; Paul Ashton; Peter A. Crooks

N-benzoyl amino acids 1a–g react with excess oxalyl chloride at room temperature followed by addition of alcohols to afford 4-substituted 2-phenyloxazole-5-carboxylates 3a–g.


Archive | 1992

Sustained release drug delivery devices

Thomas J. Smith; Paul Ashton; Paul A. Pearson


Archive | 1997

Means to Achieve Sustained Release of Synergistic Drugs by Conjugation

Paul Ashton; Peter A. Crooks; Tadeusz Cynkowski; Grazyna Cynkowska; Hone Guo


Archive | 1996

Implantable controlled release device to deliver drugs directly to an internal portion of the body

Paul Ashton; Paul A. Pearson


Archive | 1995

Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body

Paul Ashton; Roy A. Patchell; Jon Cooper; Byron Young


Archive | 1994

Codrugs as a method of controlled drug delivery

Paul Ashton; Peter A. Crooks; Robert Mack Riggs; Tadeusz Cynkowski; Grazyna Cynkowska


Archive | 1994

Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents

Paul Ashton; Thomas J. Smith; Peter Glavinos; John D. Conklin; Peter A. Crooks; Robert Mack Riggs; Tadeusz Cynkowski; Grazyna Cynkowska

Collaboration


Dive into the Paul Ashton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter A. Crooks

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Hong Guo

University of Kentucky

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas J. Smith

University of Texas Medical Branch

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pearson Pa

University of Kentucky

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J.D. Brown

University of Kentucky

View shared research outputs
Researchain Logo
Decentralizing Knowledge